Vitexin reduces epilepsy after hypoxic ischemia in the neonatal brain via inhibition of NKCC1.

Taken together, these results confirmed that vitexin effectively alleviates epilepsy susceptibility through inhibition of inflammation along with improved BBB integrity. Our study provides a strong rationale for the further development of vitexin as a promising therapeutic candidate treatment for epilepsy in the immature brain.